| Use of immunotherapy and microbiome modulation to treat cancer E HALVORSEN, C Desjardins, K BARDHAN, SD PANDIAN US Patent App. 18/546,922, 2024 | | 2024 |
| Distinct Escherichia coli transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selection MG Young, TJ Straub, CJ Worby, HC Metsky, A Gnirke, RA Bronson, ... bioRxiv, 2024 | | 2024 |
| 607 MCGRAW trial: evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients IG Oliva, O Hamid, P Ott, G Boland, R Sullivan, K Grossmann, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 6 | 2022 |
| 110: IMPACT OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, ON STOOL FATTY ACID METABOLITES IN A PHASE 3 RANDOMIZED TRIAL (ECOSPOR III) FOR TREATMENT OF RECURRENT … JA Bryant, M Vulic, C Desjardins, CB Ford, KD Litcofsky, JR Wortman, ... Gastroenterology 162 (7), S-21, 2022 | 2 | 2022 |
| Engraftment of investigational microbiome therapeutic SER-109 is durable through 24 weeks in a randomized trial (ECOSPOR III) for the treatment of recurrent Clostridioides … C Desjardins, JA Bryant, E Walsh, CB Ford, KD Litcofsky, JR Wortman, ... GASTROENTEROLOGY 162 (7), S651-S651, 2022 | 1 | 2022 |
| Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women CJ Worby, HL Schreiber IV, TJ Straub, LR van Dijk, RA Bronson, ... Nature microbiology 7 (5), 630-639, 2022 | 89 | 2022 |
| Limited effects of long-term daily cranberry consumption on the gut microbiome in a placebo-controlled study of women with recurrent urinary tract infections TJ Straub, WC Chou, AL Manson, HL Schreiber, BJ Walker, ... BMC microbiology 21, 1-17, 2021 | 24 | 2021 |
| Treatment of a cancer by microbiome modulation J Wortman, D Liyang, C Desjardins, G Marnellos, H Matthew, J Wargo, ... US Patent App. 15/733,682, 2021 | 2 | 2021 |
| SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial BH McGovern, CB Ford, MR Henn, DS Pardi, S Khanna, EL Hohmann, ... Clinical Infectious Diseases 72 (12), 2132-2140, 2021 | 131 | 2021 |
| Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors. M Sarfaty, CA Desjardins, P Giardina, K Bardhan, S Pandian, K Halley, ... Journal of Clinical Oncology 39 (15_suppl), 2574-2574, 2021 | 2 | 2021 |
| Leveraging gut microbiota networks to impact tumor immunotherapy. J Sceneay, S Srinivasan, K Halley, M Bist, K Cieciuch, G Marnellos, ... CANCER IMMUNOLOGY RESEARCH 8 (4), 26-26, 2020 | | 2020 |
| Abstract PR01: Leveraging gut microbiota networks to impact tumor immunotherapy J Sceneay, S Srinivasan, K Halley, M Bist, K Cieciuch, G Marnellos, ... Cancer Immunology Research 8 (4_Supplement), PR01-PR01, 2020 | | 2020 |
| Landscape of gene expression variation of natural isolates of Cryptococcus neoformans in response to biologically relevant stresses CH Yu, Y Chen, CA Desjardins, JL Tenor, DL Toffaletti, C Giamberardino, ... Microbial genomics 6 (1), e000319, 2020 | 29 | 2020 |
| Extensive global movement of multidrug-resistant M. tuberculosis strains revealed by whole-genome analysis KA Cohen, AL Manson, T Abeel, CA Desjardins, SB Chapman, S Hoffner, ... Thorax 74 (9), 882-889, 2019 | 29 | 2019 |
| Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges KA Cohen, AL Manson, CA Desjardins, T Abeel, AM Earl Genome medicine 11 (1), 45, 2019 | 136 | 2019 |
| 623–Ser-287, an investigational microbiome therapeutic, induces widespread transcriptional changes related to clinical remission in a placebo-controlled, double-blind … L Diao, MC Nnamani, E OBrien, C Desjardins, A Martinez, S Simmons, ... Gastroenterology 156 (6), S-130, 2019 | 5 | 2019 |
| Abstract B063: Leveraging gut microbiota networks to impact tumor immunotherapy L Jayaraman, J Sceneay, S Srinivasan, K Halley, M Bist, K Cieciuch, ... Cancer Immunology Research 7 (2_Supplement), B063-B063, 2019 | 3 | 2019 |
| Antagonistic paralogs control a switch between growth and pathogen resistance in C. elegans KC Reddy, T Dror, RS Underwood, GA Osman, CR Elder, CA Desjardins, ... PLoS pathogens 15 (1), e1007528, 2019 | 74 | 2019 |
| 621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner M Henn, C Ford, E O’Brien, J Wortman, L Diao, C Desjardins, ... Open Forum Infectious Diseases 5 (suppl_1), S226-S227, 2018 | 2 | 2018 |
| SynerClust: a highly scalable, synteny-aware orthologue clustering tool CH Georgescu, AL Manson, AD Griggs, CA Desjardins, A Pironti, ... Microbial genomics 4 (11), e000231, 2018 | 18 | 2018 |
